Biology and immunology of cancer stem(-like) cells in head and neck cancer

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 3, 2015, Pages 337-345

  Qian, Xu ^a,b   Ma, Chenming ^b   Nie, Xiaobo ^a   Lu, Jianxin ^a   Lenarz, Minoo ^b   Kaufmann, Andreas M ^b   Albers, Andreas E ^b  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ALDH1; Cancer stem cells; Epithelial mesenchymal transition; Human papillomavirus; Immunotherapy; Vaccination

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 1; CANCER STEM CELL VACCINE; CANCER VACCINE; CD98 ANTIGEN; CISPLATIN; DENDRITIC CELL VACCINE; GLYCOGEN SYNTHASE KINASE 3BETA; HERMES ANTIGEN; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS DNA;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CD8+ T LYMPHOCYTE; CELL TRANSFORMATION; CHEMORADIOTHERAPY; COLON CARCINOMA; EPITHELIAL MESENCHYMAL TRANSITION; GLIOBLASTOMA; GLIOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEAD AND NECK SURGERY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL EPITHELIAL TRANSITION; METASTASIS; NONHUMAN; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; WART VIRUS; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; HEAD AND NECK NEOPLASMS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; RADIATION RESPONSE; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; TUMOR ESCAPE;

EID: 84938215184     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.03.009     Document Type: Review

References (74)

1. Albers A.E., Chen C., Koberle B., et al. Stem cells in squamous head and neck cancer. Crit Rev Oncol Hematol 2012, 81:224-240.
2. Prince M.E., Sivanandan R., Kaczorowski A., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007, 104:973-978.
3. Pries R., Witrkopf N., Trenkle T., Nitsch S.M., Wollenberg B. Potential stem cell marker CD44 is constitutively expressed in permanent cell lines of head and neck cancer. In Vivo 2008, 22:89-92.
4. Chen C., Wei Y., Hummel M., et al. Evidence for epithelial-mesenchymal transition in cancer stem cells of head and neck squamous cell carcinoma. PLoS ONE 2011, 6:e16466.
5. Clay M.R., Tabor M., Owen J.H., et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010, 32:1195-1201.
6. Biddle A., Liang X., Gammon L., et al. Cancer stem cells in squamous cell carcinoma switch between two distinct phenotypes that are preferentially migratory or proliferative. Cancer Res 2011, 71:5317-5326.
7. Krishnamurthy S., Dong Z., Vodopyanov D., et al. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res 2010, 70:9969-9978.
8. Mitchem J.B., Brennan D.J., Knolhoff B.L., et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 2013, 73:1128-1141.
9. Kindt N., Preillon J., Kaltner H., et al. Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. J Cancer Res Clin Oncol 2013, 139:727-737.
10. Borovski T., De Sousa E.M.F., Vermeulen L., Medema J.P. Cancer stem cell niche: the place to be. Cancer Res 2011, 71:634-639.
11. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
12. Albers A.E., Strauss L., Liao T., Hoffmann T.K., Kaufmann A.M. T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. Clin Dev Immunol 2010, 2010:236378.
13. Liao T., Kaufmann A.M., Qian X., et al. Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines. J Cancer Res Clin Oncol 2013, 139:159-170.
14. Wei J., Barr J., Kong L.Y., et al. Glioma-associated cancer-initiating cells induce immunosuppression. Clin Cancer Res 2010, 16:461-473.
15. Diehn M., Cho R.W., Lobo N.A., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
16. Xu J., Muller S., Nannapaneni S., et al. Comparison of quantum dot technology with conventional immunohistochemistry in examining aldehyde dehydrogenase 1A1 as a potential biomarker for lymph node metastasis of head and neck cancer. Eur J Cancer 2012, 48:1682-1691.
17. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
18. Floor S., van Staveren W.C., Larsimont D., Dumont J.E., Maenhaut C. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene 2011, 30:4609-4621.
19. Mani S.A., Guo W., Liao M.J., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
20. Sarrio D., Franklin C.K., Mackay A., Reis-Filho J.S., Isacke C.M. Epithelial and mesenchymal subpopulations within normal basal breast cell lines exhibit distinct stem cell/progenitor properties. Stem Cells 2012, 30:292-303.
21. Shigeishi H., Biddle A., Gammon L., et al. Maintenance of stem cell self-renewal in head and neck cancers requires actions of GSK3beta influenced by CD44 and RHAMM. Stem Cells 2013, 31:2073-2083.
22. Yang W.H., Lan H.Y., Huang C.H., et al. RAC1 activation mediates Twist1-induced cancer cell migration. Nat Cell Biol 2012, 14:366-374.
23. Kong D., Li Y., Wang Z., et al. miR-200 regulates PDGF-D-mediated epithelial-mesenchymal transition, adhesion, and invasion of prostate cancer cells. Stem Cells 2009, 27:1712-1721.
24. Qian X., Wagner S., Ma C., et al. ALDH1-positive cancer stem-like cells are enriched in nodal metastases of oropharyngeal squamous cell carcinoma independent of HPV status. Oncol Rep 2013, 29:1777-1784.
25. Pang R., Law W.L., Chu A.C., et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010, 6:603-615.
26. Currie M.J., Beardsley B.E., Harris G.C., et al. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity. Hum Pathol 2013, 44:402-411.
27. Jiang F., Qiu Q., Khanna A., et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7:330-338.
28. Leemans C.R., Braakhuis B.J., Brakenhoff R.H. The molecular biology of head and neck cancer. Nat Rev Cancer 2011, 11:9-22.
29. Jung Y.S., Kato I., Kim H.R. A novel function of HPV16-E6/E7 in epithelial-mesenchymal transition. Biochem Biophys Res Commun 2013.
30. Tang A.L., Owen J.H., Hauff S.J., et al. Head and neck cancer stem cells: the effect of HPV - an in vitro and mouse study. Otolaryngol Head Neck Surg 2013, 49:252-260.
31. Rietbergen M.M., Martens-de Kemp S.R., Bloemena E., et al. Cancer stem cell enrichment marker CD98: a prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. Eur J Cancer 2014, 50:765-773.
32. Morrison R., Schleicher S.M., Sun Y., et al. Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol 2011, 2011:941876.
33. Ogawa K., Yoshioka Y., Isohashi F., et al. Radiotherapy targeting cancer stem cells: current views and future perspectives. Anticancer Res 2013, 33:747-754.
34. Chen Y.W., Chen K.H., Huang P.I., et al. Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma-derived CD44(+)ALDH1(+) cells. Mol Cancer Ther 2010, 9:2879-2892.
35. Chen Y.C., Chang C.J., Hsu H.S., et al. Inhibition of tumorigenicity and enhancement of radiochemosensitivity in head and neck squamous cell cancer-derived ALDH1-positive cells by knockdown of Bmi-1. Oral Oncol 2010, 46:158-165.
36. Bourguignon L.Y., Wong G., Earle C., Chen L. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem 2012, 287:32800-32824.
37. Boiko A.D., Razorenova O.V., van de Rijn M., et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010, 466:133-137.
38. Busse A., Letsch A., Fusi A., et al. Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells?. Clin Exp Metastasis 2013, 30:781-791.
39. Chen Y.C., Chen Y.W., Hsu H.S., et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun 2009, 385:307-313.
40. Isfoss B.L., Holmqvist B., Alm P., Olsson H. Distribution of aldehyde dehydrogenase 1-positive stem cells in benign mammary tissue from women with and without breast cancer. Histopathology 2012, 60:617-633.
41. Okamoto A., Chikamatsu K., Sakakura K., et al. Expansion and characterization of cancer stem-like cells in squamous cell carcinoma of the head and neck. Oral Oncol 2009, 45:633-639.
42. + T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res 2007, 67:10538-10545.
43. Ochsenreither S., Majeti R., Schmitt T., et al. Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen. Blood 2012, 119:5492-5501.
44. Nishizawa S., Hirohashi Y., Torigoe T., et al. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res 2012, 72:2844-2854.
45. Yamada R., Takahashi A., Torigoe T., et al. Preferential expression of cancer/testis genes in cancer stem-like cells: proposal of a novel sub-category, cancer/testis/stem gene. Tissue Antigens 2013, 81:428-434.
46. Ferris R.L., Whiteside T.L., Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res 2006, 12:3890-3895.
47. Lopez-Albaitero A., Nayak J.V., Ogino T., et al. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 2006, 176:3402-3409.
48. Leibowitz M.S., Srivastava R.M., Andrade Filho P.A., et al. SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells. Clin Cancer Res 2013, 19:798-808.
49. Ogino T., Shigyo H., Ishii H., et al. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res 2006, 66:9281-9289.
50. Xu Q., Liu G., Yuan X., et al. Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 2009, 27:1734-1740.
51. Knutson K.L., Lu H., Stone B., et al. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol 2006, 177:1526-1533.
52. Gjerdrum C., Tiron C., Hoiby T., et al. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A 2010, 107:1124-1129.
53. Kudo-Saito C., Shirako H., Takeuchi T., Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009, 15:195-206.
54. Akalay I., Janji B., Hasmim M., et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res 2013, 73:2418-2427.
55. Albers A., Abe K., Hunt J., et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 2005, 65:11146-11155.
56. Albers A.E., Ferris R.L., Kim G.G., et al. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol Immunother 2005, 54:1072-1081.
57. Hoffmann T.K., Dworacki G., Tsukihiro T., et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 2002, 8:2553-2562.
58. Bottley G., Watherston O.G., Hiew Y.L., et al. High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 2008, 27:1794-1799.
59. + oropharyngeal cancer. Oncoimmunology 2014, 3:e27254.
60. Yu C.C., Tsai L.L., Wang M.L., et al. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 2013, 73:3425-3440.
61. Duffy S.A., Taylor J.M., Terrell J.E., et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008, 113:750-757.
62. Riedel F., Zaiss I., Herzog D., Gotte K., Naim R., Hormann K. Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 2005, 25:2761-2765.
63. Duray A., Demoulin S., Hubert P., Delvenne P., Saussez S. Immune suppression in head and neck cancers: a review. Clin Dev Immunol 2010, 2010:701657.
64. deLeeuw R.J., Kost S.E., Kakal J.A., Nelson B.H. The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 2012, 18:3022-3029.
65. Ye X.Z., Xu S.L., Xin Y.H., et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-beta1 signaling pathway. J Immunol 2012, 189:444-453.
66. Jinushi M., Chiba S., Yoshiyama H., et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A 2011, 108:12425-12430.
67. Visus C., Wang Y., Lozano-Leon A., et al. Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8(+) T cells. Clin Cancer Res 2011, 17:6174-6184.
68. Ning N., Pan Q., Zheng F., et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res 2012, 72:1853-1864.
69. Duarte S., Momier D., Baque P., et al. Preventive cancer stem cell-based vaccination reduces liver metastasis development in a rat colon carcinoma syngeneic model. Stem Cells 2013, 31:423-432.
70. Ueda R., Ohkusu-Tsukada K., Fusaki N., et al. Identification of HLA-A2- and A24-restricted T-cell epitopes derived from SOX6 expressed in glioma stem cells for immunotherapy. Int J Cancer 2010, 126:919-929.
71. + T cells in prostate cancer patients. Int J Cancer 2002, 102:390-397.
72. Pellegatta S., Poliani P.L., Corno D., et al. Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 2006, 66:10247-10252.
73. Garcia-Hernandez Mde L., Gray A., Hubby B., Klinger O.J., Kast W.M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008, 68:861-869.
74. Zhang Z., Chen X., Chang X., Ye X., Li Y., Cui H. Vaccination with embryonic stem cells generates effective antitumor immunity against ovarian cancer. Int J Mol Med 2013, 31:147-153.